公开(公告)号：KR100927802B1

公开(公告)日：2009-11-23

申请号：KR1020070093994

申请日：2007-09-17

Applicant: 재단법인서울대학교산학협력재단

Inventor： 김인규 ,  전주홍 ,  신동명 ,  조성엽 ,  정의만 ,  장기용 ,  박상철

IPC: A61K31/195 ,  A61K31/132 ,  A61P27/12

CPC classification number: A61K31/195

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating cataract comprising (a) a therapeutically effective amount of a transglutaminase 2 (TGase2) inhibitor or N-acetylcysteine (NAC); and (b) a pharmaceutically acceptable carrier, and a method for screening a substance to prevent or treat cataract. The present invention definitely demonstrates molecular mechanism underlying cataractogenesis and provides a novel molecular target of cataract therapeutics. Moreover, the cataract therapeutics of this invention effectively prevent or treat cataract with much higher safety.

Abstract translation: 本发明涉及用于预防或治疗白内障的药物组合物，其包含（a）治疗有效量的转谷氨酰胺酶2（TGase2）抑制剂或N-乙酰半胱氨酸（NAC）; 和（b）药学上可接受的载体，以及筛选预防或治疗白内障的物质的方法。 本发明明确证明了白内障发生的分子机制，并提供了一种新的白内障治疗分子靶点。 而且，本发明的白内障治疗剂有效地预防或治疗白内障具有更高的安全性。

公开(公告)号：KR1020090028880A

公开(公告)日：2009-03-20

申请号：KR1020070093995

申请日：2007-09-17

Applicant: 재단법인서울대학교산학협력재단

Inventor： 김인규 ,  신동명 ,  조성엽 ,  정의만 ,  장기용 ,  박상철 ,  이동섭 ,  오근희 ,  김영환

IPC: A61K31/198 ,  A61K31/13 ,  A61P11/00 ,  A61P1/16

CPC classification number: A61K31/198

Abstract: A pharmaceutical composition including a transglutaminase(TGase 2) inhibitor or N-acetylcysteine(NAC) is provided to prevent or cure fibrosis and to specifically show the molecular mechanism about the fibrosis. A pharmaceutical composition for preventing and treating fibrosis comprises (a) pharmaceutically effective dose of a transglutaminase(TGase 2) inhibitor or N-acetylcysteine(NAC); and (b)a pharmaceutically allowable carrier. A screening method of a material for preventing and treating fibrosis comprises the steps of: (i) contacting a testing material with a transglutaminase(TGase 2) protein; and (ii) measuring the activity of the TGase 2. The transglutaminase(TGase 2) inhibitor is the cystamine or the cysteamine.

Abstract translation: 提供包含转谷氨酰胺酶（TGase 2）抑制剂或N-乙酰半胱氨酸（NAC）的药物组合物，以预防或治愈纤维化，并具体显示纤维化的分子机制。 用于预防和治疗纤维化的药物组合物包括（a）药学有效剂量的转谷氨酰胺酶（TGase 2）抑制剂或N-乙酰半胱氨酸（NAC）; 和（b）药学上可允许的载体。 用于预防和治疗纤维化的材料的筛选方法包括以下步骤：（i）使测试材料与转谷氨酰胺酶（TGase 2）蛋白质接触; 和（ii）测量TGase 2的活性。转谷氨酰胺酶（TGase 2）抑制剂是胱胺胺或半胱胺。

公开(公告)号：KR1020090028879A

公开(公告)日：2009-03-20

申请号：KR1020070093994

申请日：2007-09-17

Applicant: 재단법인서울대학교산학협력재단

Inventor： 김인규 ,  전주홍 ,  신동명 ,  조성엽 ,  정의만 ,  장기용 ,  박상철

IPC: A61K31/195 ,  A61K31/132 ,  A61P27/12

CPC classification number: A61K31/195

Abstract: A pharmaceutical composition including a transglutaminase(TGase 2) inhibitor or N-acetylcysteine(NAC) is provided to suppress the outbreak of cataract and cure the cataract and to ensure high safety on organism. A pharmaceutical composition for preventing and treating cataract comprises (a) pharmaceutically effective dose of a transglutaminase(TGase 2) inhibitor or N-acetylcysteine(NAC); and (b)a pharmaceutically allowable carrier. The transglutaminase(TGase 2) inhibitor is the cystamine or the cysteamine.

Abstract translation: 提供包含转谷氨酰胺酶（TGase 2）抑制剂或N-乙酰半胱氨酸（NAC）的药物组合物，以抑制白内障的发作并治愈白内障，并确保生物体的高安全性。 用于预防和治疗白内障的药物组合物包括（a）药学有效剂量的转谷氨酰胺酶（TGase 2）抑制剂或N-乙酰半胱氨酸（NAC）; 和（b）药学上可允许的载体。 转谷氨酰胺酶（TGase 2）抑制剂是胱胺胺或半胱胺。